Semaglutide Improved Liver Inflammation and Scarring in Advanced Fatty Liver Disease

CATEGORY: GUT & DIGESTIVE HEALTH

Weekly semaglutide injections cleared the inflammation out of the liver in 62.9% of adults whose fatty liver disease had already progressed to scarring, against 34.3% of those given a placebo over 72 weeks. Measurable scarring improved in 36.8% on the drug versus 22.4% on placebo.¹ The numbers come from a planned interim analysis of ESSENCE, a phase 3 trial still running. Until 2024 this disease had no approved drug treatment at all.

Limescale in the Kettle

The condition tested here is metabolic dysfunction-associated steatohepatitis, or MASH, known until recently as NASH. It is what fatty liver disease becomes once the fat stored inside liver cells starts to inflame the organ and swap healthy tissue for scar tissue. Doctors call that scarring process fibrosis. Scar tissue builds up in a liver much the way limescale builds up inside a kettle: the organ keeps working, but every added layer leaves it stiffer and less able to do its job. The end stage is cirrhosis, where the damage becomes largely permanent. Fibrosis is graded in stages from 0 (none) to 4 (cirrhosis), and everyone in this trial sat at stage 2 or 3.

Two Biopsies, Seventy-Two Weeks Apart

A computer decided who got the weekly shot, not the patients and not their doctors. ESSENCE enrolled 1,197 adults whose MASH had been confirmed by biopsy and split them between once-weekly semaglutide 2.4 mg and an identical-looking placebo injection, with both sides blinded. What has been reported so far is a planned interim look at the first 800 patients, 534 on semaglutide and 266 on placebo, at the 72-week mark; the trial itself runs out to 240 weeks. The headline outcomes were settled the direct way. Each patient gave a second liver biopsy, a thin needle sample of liver tissue read under a microscope, which was compared against the sample taken at the start. So the trial watched the state of the liver itself rather than blood markers or how people felt.

What Moved and What Sat Still

Both of the trial’s primary goals were met. Beyond the headline figures, 32.7% of patients on semaglutide got both wins at once, inflammation resolved and scarring lessened, compared with 16.1% on placebo. Weight fell too: 10.5% of body weight on average on the drug, versus 2.0% with placebo. Not everything moved. One prespecified secondary outcome, bodily pain scores, came out no different between the groups. The main cost was the one already familiar from semaglutide’s other uses, stomach-related complaints such as nausea, which were more common on the drug.¹

A Second Drug, a Different Route, the Same Direction

In 2024, a phase 3 randomized trial of resmetirom reported the same pattern in 966 patients over 52 weeks. Resmetirom is a once-daily pill working through an entirely different route, and the first drug approved in the United States for MASH. Liver inflammation resolved in 25.9% to 29.9% of patients on it versus 9.7% on placebo, and scarring improved by at least one stage in about a quarter versus 14.2%.² Two large randomized trials, two unrelated mechanisms, one direction of change. A liver disease long described in medical journals as untreatable now has two drugs shown to improve the organ itself. Whether those biopsy gains go on to mean fewer cases of cirrhosis and liver failure is exactly what the remaining years of the semaglutide trial are built to answer.

Key Takeaways

• Weekly semaglutide resolved MASH liver inflammation in 62.9% of patients versus 34.3% on placebo, and improved liver scarring in 36.8% versus 22.4%, over 72 weeks of a phase 3 interim analysis.
• The outcome was read off liver tissue, comparing biopsies taken before and after treatment, not off blood tests or symptoms.
• Resmetirom, a drug that works by another route entirely, produced the same pattern in a separate randomized trial, so the finding rests on more than one study and more than one mechanism.
• The trial continues. Whether tissue-level improvement translates into fewer cases of cirrhosis and liver failure is still being followed.

References

1. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. The New England Journal of Medicine. 2025;392(21):2089–2099. link
2. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. The New England Journal of Medicine. 2024;390(6):497–509. link